Phases, active trials: Phase 1: 60, Phase 2: 122, Phase 3: 192, Other: 174
AstraZeneca operates one of the broadest oncology pipelines in the industry, with particular depth in lung cancer (Tagrisso/osimertinib and successors), ovarian and breast cancer (Lynparza/olaparib), and immuno-oncology (Imfinzi/durvalumab). The AstraZeneca/Daiichi-Sankyo collaboration on antibody-drug conjugates, including Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan, has reshaped the ADC landscape across HER2-expressing tumors. Outside oncology, AstraZeneca's CVRM franchise (Farxiga/dapagliflozin, Brilinta/ticagrelor) continues expanding indications into heart failure and chronic kidney disease.
- Oncology
- Lung cancer (EGFR/ALK/HER2)
- Ovarian cancer
- Breast cancer ADCs
- Cardiovascular / Metabolic
- Rare disease
- Tagrisso (osimertinib): EGFR-mutant NSCLC
- Lynparza (olaparib): BRCA-mutated cancers
- Imfinzi (durvalumab): PD-L1 checkpoint
- Enhertu (trastuzumab deruxtecan): HER2 ADC
- Dato-DXd (datopotamab deruxtecan): TROP2 ADC
- Calquence (acalabrutinib): B-cell malignancies
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of… NCT07390240 | Primary completion moved at least 3 years later Primary endpoints removed | Recruiting |
60 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in… NCT06008093 | Oct 23, 2026 · Estimated | Phase 2 |
29 more on the Completions page. See the calendar →
Monitor the AstraZeneca pipeline daily
Get a daily digest when AstraZeneca registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Breast Cancer | 22 |
| Asthma | 17 |
| Non-small Cell Lung Cancer | 16 |
| Systemic Lupus Erythematosus | 15 |
| Non-Small Cell Lung Cancer | 14 |
| Gastric Cancer | 13 |
| Hepatocellular Carcinoma | 13 |
| Ovarian Cancer | 12 |
AstraZeneca registers new combination trials for its ADC portfolio monthly. Monitoring their pipeline helps identify new competitive entries into HER2, TROP2, and EGFR-targeted spaces before they appear in analyst reports.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to AstraZeneca's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: AstraZeneca may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your AstraZeneca pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab… NCT05984277 | Active, Not Recruiting | Completion moved earlier from Feb 28, 2029 to Nov 12, 2027 | 2026-10-10 |
| AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL NCT07215585 | Recruiting | Trial sites expanded: 68 → 82 locations | 2026-10-10 |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As… NCT06307665 | Recruiting | Trial sites expanded: 150 → 154 locations | 2026-10-10 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult… NCT06878261 | Recruiting | Trial sites expanded: 276 → 284 locations | 2026-10-10 |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With… NCT07276581 | Recruiting | Trial sites expanded: 144 → 147 locations | 2026-10-10 |
Each trial page shows every change DataLookout has recorded for that trial.